Takeda U.S. Unit Signs With Metabolex To Develop New Drugs
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceuticals' U.S. subsidiary has signed a contract with Metabolex to share research into new drugs. Metabolex of the United States specializes in treatments for diabetes and other metabolic diseases. Under the arrangement with Takeda San Francisco, the firms are to collaborate on developing a drug based on the Metabolex technology. Metabolix already has four drugs undergoing clinical trials, the most advanced of them just completed Phase II tests. (Click here for more
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.